Maganin kamuwa da cutar korona ta...?

Wani gwaji na asibiti, wanda aka buga sakamakonsa, a ranar Laraba, a cikin wata jarida ta musamman na likitanci, ya nuna cewa maganin "tofacitinib" don maganin arthritis ya nuna sakamako mai ban sha'awa a cikin kula da marasa lafiya da alamun cutar Covid-19.

Kuma gwajin asibiti, wanda aka buga sakamakonsa a cikin "Jarida ta Magunguna ta New England," ya faru a kan mutane 289 da ke jinya a asibitoci a wurare daban-daban 15 a Brazil saboda munanan alamun Covid-19.

Rabin waɗannan marasa lafiya an ba su tofacitinib (kwayoyin 10 MG guda biyu a kowace rana) a hade tare da kiwon lafiya na al'ada kuma sauran rabin an ba su wuribo tare da kiwon lafiya iri ɗaya.

Bayan kwanaki 28, kashi 18% na rukunin da suka karɓi maganin sun sami gazawar numfashi (misali buƙatar intubation ko samun damar yin numfashi) ko kuma sun mutu, idan aka kwatanta da 29% na rukunin placebo.

A cikin duka, 5.5% na marasa lafiya na placebo sun mutu, idan aka kwatanta da 2.8% a cikin rukunin tofacitinib.

Ana sayar da Tofacitinib a ƙarƙashin nau'o'i daban-daban, ciki har da Zeljans, wanda ke mallakar kungiyar Pfizer ta Amurka.

Otavio Berwanger, wani likita a Asibitin Albert Einstein a Isra'ila wanda ya gudanar da gwajin asibiti tare da haɗin gwiwa tare da Pfizer ya ce "An ƙarfafa mu da sakamakon farko na gwajin da muka yi na tofacitinib a cikin marasa lafiya da ke asibiti tare da ciwon huhu da Covid-19 ya haifar."

An yarda da Tofacitinib don amfani a Amurka don magance cututtukan cututtuka na rheumatoid, psoriatic arthritis, da ulcerative colitis.

Wasu batutuwa: 

Yaya za ku yi da wanda ya yi watsi da ku a hankali?

http://عشرة عادات خاطئة تؤدي إلى تساقط الشعر ابتعدي عنها